Matches in Wikidata for { <http://www.wikidata.org/entity/Q90685429> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q90685429 description "article scientifique publié en 2020" @default.
- Q90685429 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q90685429 description "scientific article published on 23 March 2020" @default.
- Q90685429 description "wetenschappelijk artikel" @default.
- Q90685429 description "наукова стаття, опублікована 23 березня 2020" @default.
- Q90685429 name "Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding" @default.
- Q90685429 name "Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding" @default.
- Q90685429 type Item @default.
- Q90685429 label "Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding" @default.
- Q90685429 label "Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding" @default.
- Q90685429 prefLabel "Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding" @default.
- Q90685429 prefLabel "Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding" @default.
- Q90685429 P1433 Q90685429-EBE1AF15-CBE4-45F9-9458-0BFA8D18D8A0 @default.
- Q90685429 P1476 Q90685429-1FC12691-16CF-4CC3-A4F7-AD8C7F601AFF @default.
- Q90685429 P2093 Q90685429-4AFBE807-8742-4596-8168-8CF3CB82D855 @default.
- Q90685429 P2093 Q90685429-AA55E192-6FFF-4804-9FCF-0CC049D6E169 @default.
- Q90685429 P2093 Q90685429-B303BC68-4BD0-4FB5-A535-5675E1DD870F @default.
- Q90685429 P2093 Q90685429-C9541245-2325-44D9-BBD6-8342FE49791C @default.
- Q90685429 P2093 Q90685429-F312585C-CAD3-48A4-A324-B4C4BCCC95B8 @default.
- Q90685429 P2093 Q90685429-F4035DEA-4261-4886-891B-6A81CBF1CE72 @default.
- Q90685429 P2093 Q90685429-F4AEFF57-50C3-49A3-BCBF-02F6849B41F9 @default.
- Q90685429 P2860 Q90685429-3F4A1618-FBA0-41FF-BAD3-DBE2F4560A6A @default.
- Q90685429 P31 Q90685429-41D5313C-289B-4E30-AF94-B10B2578FA79 @default.
- Q90685429 P356 Q90685429-B1ADED98-77BC-4824-A58A-CFAADA613B89 @default.
- Q90685429 P577 Q90685429-7104F8B8-E7B7-4E7B-906E-00BCDFFD1426 @default.
- Q90685429 P698 Q90685429-F32D20C7-E453-4F83-B81E-B0A74E4B65C6 @default.
- Q90685429 P356 J.JTHO.2020.03.004 @default.
- Q90685429 P698 32217131 @default.
- Q90685429 P1433 Q2448056 @default.
- Q90685429 P1476 "Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding" @default.
- Q90685429 P2093 "Alanda L Alves" @default.
- Q90685429 P2093 "Anderson R Simões" @default.
- Q90685429 P2093 "Auro Del Giglio" @default.
- Q90685429 P2093 "Barbara B Dourado" @default.
- Q90685429 P2093 "Barbara de Souza Gutierres" @default.
- Q90685429 P2093 "Pedro N Aguiar" @default.
- Q90685429 P2093 "Silvio Matsas" @default.
- Q90685429 P2860 Q24655756 @default.
- Q90685429 P31 Q13442814 @default.
- Q90685429 P356 "10.1016/J.JTHO.2020.03.004" @default.
- Q90685429 P577 "2020-03-23T00:00:00Z" @default.
- Q90685429 P698 "32217131" @default.